These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26458440)

  • 1. [Epigenetic therapy for hematologic malignancies].
    Kobayashi Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2015-23. PubMed ID: 26458440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
    Zhao A; Zhou H; Yang J; Li M; Niu T
    Signal Transduct Target Ther; 2023 Feb; 8(1):71. PubMed ID: 36797244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.
    Fratta E; Montico B; Rizzo A; Colizzi F; Sigalotti L; Dolcetti R
    Oncotarget; 2016 Aug; 7(35):57327-57350. PubMed ID: 27329599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methyltransferases in hematologic malignancies.
    Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
    Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylases and epigenetic therapies of hematological malignancies.
    Mercurio C; Minucci S; Pelicci PG
    Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy in hematological cancers.
    Dimopoulos K; Grønbaek K
    APMIS; 2019 May; 127(5):316-328. PubMed ID: 30859683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia.
    Rüter B; Wijermans PW; Lübbert M
    Int J Hematol; 2004 Aug; 80(2):128-35. PubMed ID: 15481440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A primer for epigenetics of hematological malignancies].
    Nakajima H
    Rinsho Ketsueki; 2016; 57(10):1835-1844. PubMed ID: 27725578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
    Claus R; Almstedt M; Lübbert M
    Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of hypomethylating agents in the treatment of hematologic malignancies.
    Kihslinger JE; Godley LA
    Leuk Lymphoma; 2007 Sep; 48(9):1676-95. PubMed ID: 17786703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
    [No Abstract]   [Full Text] [Related]  

  • 18. Epigenetic programming contributes to development of drug resistance in hematological malignancies.
    Wang QY; Zhong H
    Front Biosci (Landmark Ed); 2015 Jan; 20(4):728-42. PubMed ID: 25553475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epigenetics in hematological disorders].
    Furukawa Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.